NCT05291845 Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
| NCT ID | NCT05291845 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Zagazig University |
| Condition | Warts |
| Study Type | INTERVENTIONAL |
| Enrollment | 162 participants |
| Start Date | 2022-04-03 |
| Primary Completion | 2025-10-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 162 participants in total. It began in 2022-04-03 with a primary completion date of 2025-10-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy
Eligibility Criteria
Inclusion Criteria: * patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study Exclusion Criteria: * Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine
Contact & Investigator
Reham Essam, MD
PRINCIPAL INVESTIGATOR
Zagazig University
Frequently Asked Questions
Who can join the NCT05291845 clinical trial?
This trial is open to participants of all sexes, aged 9 Years or older, studying Warts. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05291845 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05291845 currently recruiting?
Yes, NCT05291845 is actively recruiting participants. Contact the research team at rereessam22@gmail.com for enrollment information.
Where is the NCT05291845 trial being conducted?
This trial is being conducted at Zagazig, Egypt.
Who is sponsoring the NCT05291845 clinical trial?
NCT05291845 is sponsored by Zagazig University. The principal investigator is Reham Essam, MD at Zagazig University. The trial plans to enroll 162 participants.